Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: A European multicenter double-blind trial  by Meyer, Guy et al.
JACC Vol. 19, No. 2 
February 1992:239-45 
COOPERATIVE STUDIES 
239 
Effects of Intravenous Urokinase Versus Alteplase on Total Pulmonary 
Resistance in Acute Massive Pulmonary Embolism: A European 
Multicenter Double-Blind Trial 
GUY MEYER, MD, HERVE SORS, MD, BERNARD CHARBONNIER, MD,* 
WOLFGANG KASPER, MD,t JEAN-PIERRE BASSAND, MD,:j: IAN H. KERR, MD,§ 
EMMANUEL LESAFFRE, PHD,II PHILIPPE VANHOVE, MD,~ MARC VERSTRAETE, MD,~ 
ON BEHALF OF THE EUROPEAN COOPERATIVE STUDY GROUP FOR PULMONARY EMBOLISM** 
Paris, Tours and Besam;on, France; Freiburg, Germany; London, England; Leuven, Belgium 
Twelve centers participated in a double-blind study in which 63 
patients with angiographically documented acute massive pulmo-
nary embolism were randomly assigned to treatment with either 
urokinase (4,400 U/kg as an intravenous bolus infusion, then 
4,400 U/kg per h over 12 h; n = 29) or alteplase (10 mg as an 
intravenous bolus infusion, then 90 mg over 2 h) followed by 
heparin (n = 34). The primary objective was to compare the 
resolution of pulmonary embolism as judged by the change in total 
pulmonary resistance over the initial 2 h. Further objectives were 
to evaluate the changes in total pulmonary resistance over the next 
10 h and the degree of angiographic resolution at 12 to 18 h. 
At 2 h, total pulmonary resistance decreased by 18 ± 22% in 
the urokinase group and by 36 ± 17% in the alteplase group (p = 
Urokinase and streptokinase have been widely studied in the 
treatment of pulmonary embolism (1) and demonstrated to 
have a superior effect on early resolution of pulmonary 
embolism compared with heparin alone (2-4). In addition, 
unlike heparin, these agents can achieve a significant hemo-
dynamic improvement within a few hours in patients with 
massive pulmonary embolism (5,6). The thrombolytic effects 
of various regimens of urokinase and streptokinase were 
reported (7 ,8) to be similar and it is currently recommended 
(9) that patients requiring thrombolytic therapy receive 
either a 12-h urokinase infusion or a 24-h streptokinase 
infusion. Recently (10-12), alteplase was shown to be a 
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0.0009). Continuous monitoring of pulmonary artery mean pres-
sure, cardiac index and total pulmonary resistance revealed that 
these variables improved faster in the alteplase group, with 
consistently significant intergroup differences from 30 min up to 3 
to 4 h. 
After 12 h, the decrease in total pulmonary resistance was 53 
± 19% in the urokinase group compared with 48 ± 17% in the 
alteplase group and the reduction in the angiographic severity 
score was 30 ± 25% compared with 24 ± 18%, respectively, with 
no significant intergroup differences. Bleeding was equally fre-
quent in the two treatment groups, except that more urokinase-
treated patients experienced hematomas at puncture sites. 
(JAm Coli Cardio/1992;19:239-45) 
potent thrombolytic agent in patients with acute pulmonary 
embolism. However, experience with this drug is still limited 
and only a few randomized studies have been conducted to 
compare the efficacy and side effects of alteplase versus 
urokinase (13) or heparin alone (14,15). 
The purpose of the present study was to compare a 2-h 
intravenous infusion of alteplase followed by a 10-h infusion 
of heparin with a 12-h intravenous infusion of urokinase. The 
primary objective was to compare the rate and extent of 
resolution of acute massive pulmonary embolism as judged 
by the change in total pulmonary resistance over the initial 
2 h. Further objectives were to evaluate the changes in total 
pulmonary resistance over the next 10 h, compare the degree 
of angiographic resolution at 12 to 18 hand assess the safety 
of both treatment regimens over the total period of hospital-
ization. 
Methods 
The trial was designed as a randomized, double-blind, 
double-dummy study. Before joining the study, each center 
had to test the feasibility of the protocol requirements in a 
nonrandomized patient. The study protocol was approved 
by the European Ethical Review Committee. 
0735-1097/92/$5.00 
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Patient enrollment. Patients aged between 18 and 75 
years with the onset of symptoms suggestive of acute 
massive pulmonary embolism in the preceding 5 days were 
considered for the study. After informed consent was ob-
tained, patients underwent cardiac catheterization and mea-
surement of pulmonary artery pressure. A pulmonary artery 
systolic or mean pressure > 70 or 50 mm Hg, respectively, 
excluded the patient from entry into the study. After these 
procedures, pulmonary angiography was performed and all 
patients meeting the entry criteria had to have an initial 
Miller angiographic score (16) of ~20/34 (that is, pulmonary 
vascular obstruction ~59%) as judged by the physician in 
charge. 
The exclusion criteria were significant preexistent cardiac 
or pulmonary disease (except premonitory symptoms of 
minor pulmonary embolism in the preceding month), recent 
puncture of a noncompressible vessel or organ biopsy, 
application of a vena caval filter or current treatment with 
coumarin, pregnancy, head trauma or cerebrovascular acci-
dent in the preceding 6 months, history of cerebral hemor-
rhage, intracranial or intraspinal surgery, bleeding disorder 
or platelet count < 100,000/mm3 at admission, proliferative 
or hemorrhagic diabetic retinopathy, systolic blood pressure 
> 180 mm Hg or diastolic blood pressure > 110 mm Hg, or 
both, known dissecting or other aneurysm, major surgery or 
trauma in the preceding 10 days, known pericarditis or 
endocarditis, occurrence of allergic reactions, severe hypo-
tension or cardiac arrest during initial pulmonary angiogra-
phy and previous thrombolytic therapy for the same pulmo-
nary embolism. 
Pulmonary angiography. A selective bilateral pulmonary 
angiogram was obtained, preferably through brachial vein 
access, before initiation of thrombolytic treatment. Stan-
dard, large format, cut film angiograms or cineangiograms 
were required. Angiography was repeated 12 to 18 h after the 
initiation of thrombolytic treatment. 
The coded angiograms were reviewed by a panel of five 
experienced readers unaware of the chronologic order of the 
angiograms and study treatment. The severity of embolism 
was assessed by the method of Miller et al. (16). The 
individually allocated scores were reviewed by the panel and 
a consensus score was derived. 
Treatment protocol. Random treatment allocation was 
balanced at each center in blocks of four. The alteplase 
group received recombinant human, predominantly single 
chain, tissue-type plasminogen activator (Actilyse, Boehr-
inger Ingelheim). Patients weighing >65 kg were given 10 mg 
through a peripheral vein as an initial bolus infusion, fol-
lowed by 90 mg over 2 h. Patients weighing ::::::65 kg were 
given a 7-mg bolus infusion, followed by 63 mg over 2 h. 
After discontinuation of alteplase, unfractionated heparin 
(Liquemin, F. Hoffmann-La Roche & Co. Ltd.) was given as 
a continuous intravenous infusion of 20 U/kg per h over the 
next 10 h. 
In the urokinase group (Alphakinase, Green Cross Cor-
poration), the treatment was the one specified for phase I of 
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the Urokinase Pulmonary Embolism Trial (2) and approved 
by the U .S. Food and Drug Administration in 1977 (that is, 
4,400 U/kg as an intravenous bolus infusion, followed by 
4,400 U/kg per h infused over 12 h). Two separate intrave-
nous lines were used for the active study treatment and 
matching placebo. After the 12-h study treatment, all pa-
tients received a heparin infusion of 20 U/kg per h until the 
final pulmonary angiogram was obtained. 
Thrombolytic agents other than the study medication, 
antiplatelet drugs and anticoagulants other than heparin 
were not allowed before the final pulmonary angiograms 
were obtained. Drugs affecting hemodynamics and oxygen 
administration were allowed, but the dosage was kept as 
constant as possible during the 12 to 18 h of the study. 
Hemodynamic measurements. Measurements were made 
before the start of therapy (baseline) and at 0.5, 1, 1.5, 2, 3, 
4, 6, 8, 10 and 12 h thereafter. The measurements included 
respiration and heart rate, systolic and diastolic systemic 
blood pressures, right atrial mean pressure, pulmonary ar-
tery systolic, diastolic and mean pressures and cardiac 
output (three measurements). Right heart pressures and 
cardiac output were measured with a Swan-Ganz thermodi-
lution catheter inserted after the initial angiographic study. 
Total pulmonary resistance (U/m2) was calculated as total 
pulmonary resistance = pulmonary artery mean pressure 
(mm Hg)/cardiac index (liters/min per m2). Hemodynamic 
data were reviewed for consistency and accuracy by a panel 
of four experienced physicians unaware of the study treat-
ment. 
Hematologic and hemostatic measurements. Blood sam-
ples for local determination of hemoglobin, hematocrit and 
plasma fibrinogen were taken before thrombolytic treatment 
and at 2, 4, 12, 24 and 48 hand 10 to 14 days thereafter. To 
determine fibrinogen levels, blood was drawn into citrate 
(final concentration 0.01 mol/liter) with aprotinin (final con-
centration 150 kallikrein inactivator U/ml). 
Adverse events. Adverse events were noted throughout 
the hospital stay. Specifically, the following bleeding com-
plications were recorded: hemorrhagic stroke confirmed by 
computed tomography, hematomas >5 cm in diameter and 
prolonged external bleeding at puncture sites, retroperito-
neal, gastrointestinal, mediastinal, pleural, pericardial and 
gingival bleeding, hemoptysis, epistaxis and hematuria. 
Blood transfusion and the need for surgery or any other 
special measure to control bleeding were also recorded. 
Major bleeding was prospectively defined as bleeding that 
required blood transfusion, surgical control or discontinua-
tion of the study treatment, bleeding causing a decrease > 15 
percentage points in hematocrit or ~50 g/liter in hemoglobin 
level and hemorrhagic stroke confirmed by computed tomog-
raphy or autopsy. 
Statistical analysis. Calculations of sample size showed 
that it was necessary to have 64 patients in each treatment 
group to demonstrate a difference of 10 points between 
treatment groups in percent reduction of total pulmonary 
resistance at 2 h from baseline at a power of 80% and a level 
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of significance of 0.05 (two-tailed t test). This requirement 
assumes that the reduction in percentage points of total 
pulmonary resistance is approximately normally distributed 
with a standard deviation of about 20. In the intention to 
treat analysis, all data from randomized patients were used. 
In the explicative analysis, the following data were excluded 
before unblinding the trial: 1) hemodynamic data obtained 
after premature discontinuation of study treatment; 2) final 
pulmonary angiogram if study treatment was given for <80% 
of intended time; 3) initial and final pulmonary angiograms 
and all hemodynamic data from patients with protocol vio-
lation on an exclusion crjterion (see Results); and 4) hemo-
globin, hematocrit and fibrinogen levels after blood transfu-
sion. In addition, selected hemodynamic data were excluded 
from the explicative analysis (before unblinding the trial) 
because of 1) hemodynamically significant arrhythmia; 
2) dose changes in drugs with potential influence on hemo-
dynamics; 3) use of a respirator; 4) hypovolemia due to 
bleeding; 5) cardiac tamponade; and 6) obviously aberrant 
values due to a technical problem. 
Categoric data were compared with a Fisher exact test 
(2 x 2 table) or according to Mehta and Pate! (17) (r x c 
table). Continuous measures were compared between the 
treatment groups with the t test or Wilcoxon test as appro-
priate. Normality was evaluated with the Shapiro-Wilk sta-
tistic (threshold value: p = 0.10). Repeated measures anal-
ysis of variance was performed for hemodynamic variables 
and was limited to patients with a complete set of data for a 
given variable. All values are expressed as mean values ± 
1 SD unless otherwise stated. All reported p values are 
two-sided. A p value < 0.05 was considered statistically 
significant. Calculations were made with the Statistical Anal-
ysis System statistical package (18). 
Results 
Study patients (Table 1). A total of 63 patients were 
randomized between November 1988 and January 1990. 
Twenty-nine patients were assigned to urokinase and 34 to 
alteplase. In January 1990, the Data Monitoring and Ethical 
Committee reviewed the safety data and recommended 
discontinuation of the study because of five cases of pericar-
dial bleeding related to cardiac catheterization. 
Both groups were well matched. In retrospect, two pa-
tients in the alteplase group should not have entered the trial 
because of chronic pulmonary hypertension in one and in the 
other, unconfirmed massive pulmonary embolism on central 
reading of the initial angiogram. 
Only part of the study medication ( <80% of the intended 
dose) was given to three patients in the urokinase group 
(because of hemorrhage in two and too slow an infusion rate 
of urokinase in one) and five patients in the alteplase group 
(because of bleeding in four and profound hypofibrinogen-
emia in one). 
The final pulmonary angiogram was not obtained in one 
patient in the urokinase group because of inaccessible veins 
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Table 1. Patient Baseline Characteristics* 
Urokinase Alteplase 
Group Group 
No. of patients 29 34 
Male/female ratio 12/17 18/16 
Age (yr) 60 ± 13 60 ± 15 
Weight (kg) 74 ± 13 75 ± 12 
Symptom duration (h) 26 ± 22 36 ± 33 
No. of patients (%) with 
Symptoms of minor PE in past month 17 (59) 17 (50) 
Deep vein thrombosis 15 (52) 13 (38) 
Prolonged immobilization 10 (34) 14 (41) 
Surgery in past month 7 (24) 12 (35) 
Malignancy I (3) 5 (15) 
Pretreatment SBP <90 mm Hg 3 (10) 4 (12) 
Cardiogenic shock 0 (0) 4 (12) 
SBP (mm Hg) 124 ± 19 122 ± 26 
Heart rate (beats/min) 101 ± 20 106 ± 26 
Respiratory rate (breaths/min) 24 ± 7 24 ± 6 
Pra (mm Hg) 7 ± 4 6 ± 5 
PAPs (mm Hg) 48 ± 16 49 ± 13 
PAPd (mm Hg) 17 ± 4 17 ± 5 
PAPm(mm Hg) 28 ± 8 29 ± 7 
Cl (liters/min per m2) 2.2 ± 0.5 2.5 ± 0.7 
TPR (U/m2) 14.1 ± 6.0 12.4 ± 4.7 
Angiographic score 25 ± 2 24 ± 4 
*No differences were found between the treatment groups at a p level of 
0.1. Values are expressed as mean values ±SO. Cl = cardiac index; 
PAPs,d,m = pulmonary artery systolic, diastolic, mean pressure, respec-
tively; PE = pulmonary embolism; Pra = right atrial mean pressure; SBP = 
systolic blood pressure; TPR = total pulmonary resistance. 
and in three patients in the alteplase group because of early 
pericardial drainage and pulmonary embolectomy (two pa-
tients) and death (one patient). In these last three patients, 
hemodynamic monitoring was prematurely interrupted. In 
14 additional patients (6 in the urokinase group and 8 in the 
alteplase group), some hemodynamic values were not ob-
tained at one or more time points because of technical 
reasons. 
Hemodynamic Results 
Explicative analysis (Table 2). The results of continuous 
monitoring of the pulmonary artery mean pressure, cardiac 
index and total pulmonary resistance are shown in Figure 1. 
In both groups, these variables improved over time but 
faster in the alteplase group, with consistently significant 
intergroup differences from 30 min up to 3 to 4 h, depending 
on the variable. Repeated measures analysis of variance 
showed that the changes in pulmonary artery mean pressure 
and total pulmonary resistance over 12 h were significant in 
both treatment groups (time effect: p :::; 0.0001) and different 
between the two groups (interaction treatment x time: p = 
0.03 and p:::; 0.0001, respectively). Changes in cardiac index 
over 12 h were significant in the urokinase but not in the 
alteplase group (time effect: p = 0.0002 and p = 0.08, 
respectively) and were different between the two treatment 
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Table 2. Hemodynamic Data at Baseline and at 2 and 12 h (explicative analysis) 
Urokinase Group Alteplase Group 
Baseline 2h 12 h Baseline 2h 12 h 
SBP (mm Hg) 124 :±: 19 127 :±: 16 136 :±: 26 119 :±: 24 128 :±: 17 132 :±: 20 
DBP(mm Hg) 80 :±: 11 79 :±: 9 78 :±: 13 75 :±: 15 78 :±: 12 79 :±: 14 
HR (beats/min) 99 :±: 15 92 :±: 15 84 :±: 14 106 :±: 24 94 :±: 21 90 :±: 16 
RR (breaths/min) 24 :±: 7 22 :±: 7 21 :!: 5 25:!: 6 23 :±: 5 22 :±: 4 
Pra (mm Hg) 7 :±: 4 7 :±: 4 5 :!: 3 6 :±: 5 4 :±: 4 3 :±: 4 
PAPs (mm Hg) 48 :±: 16 41 :±: 12 30 :!: 11 47 :±: 12 33 :±: 8 30:!: 10 
PAPd (mm Hg) 17 :±: 4 14 :±: 4 10:!: 4 16 :±: 5 11 :±: 4 10 :±: 4 
PAPm (mm Hg) 28 :±: 7 23 ± 6 17 :±: 6 28 :±: 7 20 :±: 5 17 :±: 6 
Cl (liters/min per m2) 2.2 :±: 0.5 2.3 :±: 0.6 2.9 :±: 0.6 2.6 :±: 0.7 3.0 :±: 0.7 3.0 :±: 0.4 
TPR (U/m2) 14.1 :±: 6.0 11.1 :±: 4.5 6.4:!: 2.7 11.9:±:4.4 6.9 :±: 2.1 5.9 :±: 2.2 
Values expressed as mean values :±:SO. DBP= diastolic blood pressure; HR = heart rate; RR = respiratory rate; other abbreviations as in Table I. 
groups (interaction treatment x time: p = 0.0025). There 
were further significant changes in total pulmonary resis-
tance over time between 2 h and 12 h in the urokinase and 
alteplase groups (time effect: p s 0.0001 and p = 0.0016, 
respectively) and these changes were different between the 
treatment groups (interaction treatment x time: p = 0.0006). 
In the total study group, alteplase had a greater effect on 
cardiac index at 2 h than urokinase ( + 18 ± 16% vs. + 7 ± 
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19%; p = 0.0174). In a subgroup of patients (not prospec-
tively defined) with a baseline cardiac index s 2.5 liters/min 
per m2 (21 patients in the urokinase group and 18 in the 
alteplase group), alteplase had an even more pronounced 
effect than urokinase on cardiac index at 2 h ( + 24 ± 15% vs. 
+ 7 ± 18%; p = 0.0056). 
2 
Although the hemodynamic and other vital variables were 
measured repeatedly, only the values obtained at baseline 
4 6 8 10 12 
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g Figure l. Mean pulmonary artery mean pressure (PAPm) (top left), cardiac index (Cl) 
~ 70 (top right) and total pulmonary resistance (TPR) (bottom left) expressed as percent of 
o._ the preinfusion value at different time intervals after the start of the intravenous f-
infusion of urokinase (closed circles) and alteplase (open circles). Data are mean values 60 
± SEM . 
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and 2 and 12 h after the start of treatment are given in Table 
2. Systemic blood pressure, heart and respiration rates and 
right atrial mean pressure progressively improved in each 
treatment group without consistently significant intergroup 
differences. 
Intention to treat analysis. In the urokinase group, total 
pulmonary resistance decreased from 14.1 ± 6 U at baseline 
to 11.1 ± 4.5 U at 2 hand to 6.1 ± 2.7 U at 12 h. In the 
alteplase group, corresponding values were 12.4 ± 4.7, 7.7 ± 
3.6 and 5.8 ± 2.1 U. At 2 h, total pulmonary resistance 
decreased from baseline by 18 ± 22% in the urokinase group 
(n = 29) and by 36 ± 17% in the alteplase group (n = 34) 
(p = 0.0009). At 12 h, the decrease in total pulmonary 
resistance from baseline was 53 ± 19% in the urokinase 
group (n = 29) and 48 ± 17% in the alteplase group (n = 31), 
with no significant intergroup difference (p = 0.14). 
Pulmonary Arteriograms (explicative analysis) 
In 28 patients in the urokinase group and 29 in the 
alteplase group for whom paired sets of angiograms were 
available, the angiographic score decreased by 7.5 ± 6.2 and 
5.9 ± 4.3 points, respectively (p = 0.25). 
Hematologic and Hemostatic Results 
(explicative analysis) 
In the two treatment groups, there was a mean decrease 
of about 14% from baseline to nadir levels of hemoglobin and 
hematocrit at 48 h. Fibrinogen, as assessed at each center, 
decreased faster in the alteplase-treated patients, with the 
observed nadir at 12 h in both treatment groups (-58% and 
-61% from baseline in the urokinase and alteplase groups, 
respectively; p = 0.71). 
Adverse Events and Clinical Course 
(intention to treat analysis) 
Bleeding. Bleeding complications occurred in 18 patients 
(62%) in the urokinase group and in 14 (41%) in the alteplase 
group (p = 0.13). All of these except one in the alteplase 
group (retroperitoneal bleeding) started within 48 h after 
therapy was initiated. There were no significant intergroup 
differences in the bleeding rates except that hematomas at 
puncture sites occurred more frequently in the urokinase 
group (Table 3). Major bleeding was observed in eight 
patients (28%) in the urokinase group and 7 (21%) in the 
alteplase group (p = 0.56) (Table 4). 
Mortality. Four patients died within the 14-day study 
period. In the alteplase group, three patients died as a result 
of massive recurrent pulmonary embolism on day 14 (one 
patient), acute leg ischemia on day l3 (one patient) or 
cardiac tamponade after right ventricular wall perforation at 
12 h (one patient). One patient in the urokinase group died 
from massive meningocerebral hemorrhage 22 h after initia-
tion of treatment. 
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Table 3. Number of Patients(%) With Bleeding Complications* 
Urokinase Alteplase 
Group Group 
Cerebral hemorrhage I (3) 0 (0) 
Hematoma (>5 cm) at puncture site 16 (55) 8 (24) 
Prolonged (> 30 min) external bleeding 2 (7) 2 (6) 
at puncture site 
Retroperitoneal bleeding 0 (0) I (3) 
Pericardial bleeding 0 (0) 3 (9) 
Hematemesis I (3) 0 (0) 
Epistaxis 0 (0) I (3) 
Macroscopic hematuria 0 (0) 2 (6) 
Bleeding at other sites 5 (17) 4 (12) 
Totalt 18 (62) 14 (41) 
*No significant differences were found between the treatment groups, 
except for hematoma at puncture site (p = 0.0018). tPatients with multiple 
complications were counted once. 
Cardiac perforation during catheterization and stroke. 
Cardiac perforation was reported in five patients, all in the 
alteplase group. In three of them, hemorrhagic cardiac 
tamponade occurred after the initial catheterization. Emer-
gency surgical pericardial drainage and pulmonary embolec-
tomy were performed in two, of whom one died 18 days later 
from nosocomial pneumonia (not included in the 14-day 
mortality data). The third patient (mentioned earlier) died 
12 h after the start of treatment. Two patients had cardiac 
perforation at the time of the final angiography, but their 
subsequent clinical course was uneventful. Thromboembolic 
stroke occurred in a patient with atrial fibrillation in the 2nd 
week after alteplase treatment. 
Recurrent pulmonary embolism. This was diagnosed in 
two urokinase-treated patients on the basis of clinical symp-
toms and scintigraphic signs. In one patient in the alteplase 
group, recurrent pulmonary embolism was suspected be-
cause of transient hemodynamic changes and atypical clini-
cal signs. In another patient, fatal massive recurrent pulmo-
nary embolism occurred 14 days after treatment with 
alteplase (mentioned earlier). 
Table 4. Number of Patients(%) With Major 
Bleeding Complications* 
Cerebral hemorrhage 
Blood transfusion 
Surgical control of bleeding 
Discontinuation of study treatment 
because of bleeding 
Decrease > 15% points in hematocrit or 
>50 g/liters in hemoglobin, or both 
Totalt 
Urokinase 
Group 
I (3) 
4 (14) 
0 (0) 
2 (7) 
3 (10) 
8 (28) 
Alteplase 
Group 
0 (0) 
5 (15) 
2 (6) 
4 (12) 
2 (6) 
7 (21) 
*No significant differences were found between the treatment groups. 
tPatients with multiple complications were counted once. 
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Discussion 
Study findings. The present study was designed to com-
pare the hemodynamic efficacy of two thrombolytic regi-
mens. As compared with a 12-h infusion of urokinase, 
100 mg of alteplase infused over 2 h induced faster hemody-
namic improvement (especially when the baseline cardiac 
index was low) with comparable bleeding rates and angio-
graphic and hemodynamic improvement at 12 h. We selected 
the 100-mg alteplase dosage because of its well documented 
efficacy and safety in pulmonary embolism (12,13) and the 
12-h regimen of urokinase in the Urokinase Pulmonary 
Embolism Trial (2) approved by the U.S. Food and Drug 
Administration and still considered the reference therapy for 
massive pulmonary embolism (9). 
Comparison with previous studies. The present study 
contrasts with a previous comparison (13) of urokinase and 
alteplase in acute pulmonary embolism, where urokinase 
was administered during 24 h (that is, at a dosage twice that 
used in the Urokinase Pulmonary Embolism Trial [2] and the 
present study). In addition, the present trial was double-
blind and bilateral pulmonary angiography rather than angi-
ography of the most affected side was performed. Finally, 
hemodynamic variables were continuously monitored over 
the 1st 12 hand the main evaluation criterion was the early 
change in total pulmonary resistance rather than the angio-
graphic improvement. In massive pulmonary embolism, the 
relation between total pulmonary resistance and pulmonary 
vascular obstruction shows a hyperbolic tendency, with a 
major increase in total pulmonary resistance when vascular 
obstruction is > 60% (6). Thus, in severely affected patients, 
the reduction in the angiographic score is a less sensitive 
indicator of pulmonary revascularization than is the de-
crease in total pulmonary resistance. 
In the study of Goldhaber et al. (13), pulmonary artery 
pressure was measured at 2 h and its decrease from baseline 
was found to differ significantly between the two treatment 
groups, in favor of the alteplase regimen. This finding is 
extended by the present trial, which reveals a significantly 
greater initial improvement (at 3 to 4 h) in pulmonary artery 
mean pressure, cardiac index and total pulmonary resistance 
in the alteplase group, although later changes (up to 12 h) 
were similar in both groups. Likewise, changes in angio-
graphic score at 12 to 18 h did not differ in patients receiv!ng 
the alteplase or urokinase regimens. This latter observatiOn 
is in line with the previous finding by Goldhaber et al. (13) 
that lung scan reperfusion at 24 h was similar in the uroki-
nase and alteplase groups. Thus, in both our study and 
that of Goldhaber et al. (13), the 2-h 100-mg alteplase 
infusion induced a faster hemodynamic improvement than 
the 12- and 24-h urokinase regimens, although the antithrom-
botic efficacy of alteplase and urokinase was similar at 12 
to 24 h. 
Early reversal of hemodynamic disturbances is the pri-
mary objective of the treatment of massive pulmonary 
embolism, especially in the most severely affected patients. 
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From this perspective, the thrombolytic regimen resulting 
in a faster reduction in total pulmonary resistance may 
induce a rapid clinical hemodynamic recovery and thus 
lower the early mortality rate in acute massive pulmonary 
embolism, a hypothesis that can only be tested in a much 
larger trial. 
In the present study, the incidence of bleeding was similar 
in alteplase- and urokinase-treated patients, although more 
urokinase-treated patients experienced hematomas at punc-
ture sites. The rather high overall bleeding rate (28% and 
21% of major bleeding episodes in the urokinase and alte-
plase groups, respectively) was similar to that observed in 
the Urokinase Pulmonary Embolism Trial (2) and may have 
originated in a broad and prospective definition of major 
bleeding episodes as well as the occurrence of three cases of 
hemorrhagic tamponade. These latter complications were 
due to cardiac perforation, which was probably related to the 
use of rigid angiographic catheters in some centers, rather 
than to the continuous hemodynamic monitoring required by 
the trial protocol. 
Considerations for future studies. Because high dose, 
short duration systemic treatment with streptokinase or 
urokinase has proved effective in acute myocardial infarc-
tion, a comparable short-term treatment with urokinase ?as 
been proposed in patients with acute pulmonary embolism 
(19) and is currently being investigated (20). In addition, a 
bolus infusion of 15,000 to 20,000 U/kg of urokinase was 
shown to induce a rapid decrease in t!ltal pulmonary 
resistance within 3 to 6 h (5,6) and angiographic improve-
ment at 12 to 48 h (5,6,21). This regimen was not associated 
with severe hemorrhagic complications (6,21), but was not 
prospectively evaluated on a large scale basis. Similarly, 
studies (22,23) have shown that a bolus injection of 
alteplase was effective in producing accelerated thromboly-
sis in experimental canine pulmonary embolism. Finally, 
bolus administration of alteplase was recently reported (15) 
to be successful in achieving scintigraphic improvement 
in patients with acute pulmonary embolism and causing 
only minor bleeding. However, further trials will be neces-
sary to assess the efficacy and safety of urokinase and 
alteplase bolus regimens against currently recommended 
dosages. 
Appendix 
European Cooperative Study Group for Pulmonary Embolism 
Steering Committee 
M. Verstraete, Chairman; P. Besse; M. Brochier; H. Just; C. G. Olsson ; 
W. Schmidt; H. Sors. 
Data Monitoring and Ethical Committee 
M. Demedts; K. Van de Woestijne. 
Angiography Assessment Group 
I. H. Kerr, Chairman; B. Charbonnier; G. Meyer; M. Ruttley ; J. Ver-
schakelen. 
Hemodynamic Evaluation Panel .. 
H. Sors, Chairman; B. Charbonnier; G. Simonneau; W. W1JnS. 
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Participating Clinical Centers 
Belgium: Cliniques Universitaires Saint-Luc, Brussels (J. Col: M. Goe-
nen ; J. Renkin; M. Reynaert); Universitair Ziekenhuis Gasthuisberg, Leuven 
(M. Verstraete; F. Van de Werf). 
Federal Republic of Germany: Klinikum der Albert-Ludwigs-Universitiit, 
Freiburg (H. Just; W. Kasper; T. Meinertz; N. Tiede); Medizinische Klinik 
und Poliklinik, Georg-August-Universitiit, Gottingen (U. Tebbe). 
France: Centre Hospitalier Regional, Besan~on (J. P. Bassand; T. Angue-
not; F. Schiele); Centre Hospitalier Regional et Universitaire, Marseille (M. 
Bory; A. Elias; P. Villain); Centre Hospitalier Regional et Universitaire, 
Nancy (A. Larcan; P. Bauer; M. C. Laprevote-Heully): Centre Hospitalier 
Regional, Nice (P. Morand; D. M. Drici ; S. Bossan) ; H6pital Laennec, Paris 
(H. Sors; G. Meyer); Centre Hospitalier Regional et Universitaire, Tours (M . 
Brochier; B. Charbonnier; M. Lang; G. Pacouret). 
Spain: Hospital Virgen del Rocio, Sevilla (F. Rodriguez Panadero; P. 
Alberich Sotomayor; P. Camacho Laraiia; I. Marmesat Rios; L. Martin 
Alburquerque; A. Mayo! Dey'a). 
The Netherlands: Academisch Ziekenhuis. Maastricht (H.J.J. Wellens; C. 
de Zwaan). 
Trial Monitoring 
Belgium: H. Goethals. 
Germany: W. Haarmann. 
France: T. Danays; R. Cariou; S. Bulle: G. Laginha; C. Saussine. 
Spain: M. Ruiz; S. Lessner. 
The Netherlands: R.G.L. van Tol. 
Statistics Center 
E. Lesaffre; I. Scheys; H. Deckers. 
Coordinating Center 
P. Vanhove. 
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